DOCK2 and neoplasm: In contrast, methylated ctDNA was detected in 89.2% (25/28) of mPCa patients with high tumor volume; 20/28 (71.4%) patients positive for DOCK2, 25/28 (89.2%) positive for HAPLN3, and 13/17 (76.5%) positive for FBXO30 (Figure 5A–C).